Physician profile
Thuy T Le
NPI 1588705750
$16,897.68
in general payments reported to CMS, 2019-2025
43 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,162 · 2020: $890 · 2021: $2,986 · 2022: $4,268 · 2023: $2,077 · 2024: $3,234 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,611 · Travel and Lodging: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,611.35 |
| Travel and Lodging | $1,980.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,040.42 | 2019-2025 | Aveir, Agilis, Gallant |
| Boston Scientific Corporation | $3,124.69 | 2019-2025 | General - Therapies, Rhythmia Mapping System, General - Ep |
| Novartis Pharmaceuticals Corporation | $993.39 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $875.35 | 2019-2024 | |
| Pfizer INC. | $815.37 | 2019-2025 | |
| Biosense Webster, INC. | $627.17 | 2021-2024 | Carto 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $541.80 | 2021-2025 | Jardiance |
| Medical Device Business Services, INC. | $473.38 | 2019 | |
| Medtronic, INC. | $423.63 | 2022-2024 | Selectsecure, Micra, Aurora Ev-Icd Mri Surescan |
| Janssen Pharmaceuticals, INC | $417.71 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $306.67 | 2023-2024 | Pascal, Evoque |
| Astrazeneca Pharmaceuticals LP | $288.06 | 2019-2024 | Farxiga |
| Amgen INC. | $278.72 | 2019-2025 | Repatha, Repatha |
| Abbvie INC. | $266.49 | 2021 | |
| Cardiva Medical, INC. | $248.54 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Savvywire, Cardiva Vascade Mvp Xl Vvcs 10-12f |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $229.46 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $226.74 | 2022-2025 | Verquvo, Capvaxive |
| Kestra Medical Technology Services, INC. | $185.27 | 2022-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $170.32 | 2021-2025 | Lifevest |
| Astellas Pharma US INC | $160.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $151.18 | 2023-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $134.72 | 2021-2022 | |
| Biotronik INC. | $108.42 | 2025 | Pantera Leo, Pk Papyrus, Recross |
| Cvrx, INC. | $97.65 | 2022-2025 | Barostim Neo System |
| Centrix INC | $94.89 | 2019 | |
| Philips North America LLC | $63.30 | 2023-2024 | (Bs2) Lm Undivided |
| Scpharmaceuticals INC. | $55.86 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $50.83 | 2022 | |
| Novo Nordisk INC | $48.69 | 2024 | Ozempic |
| Cardiovascular Systems INC. | $46.90 | 2019-2021 | |
| Esperion Therapeutics, INC. | $45.68 | 2021 | |
| Lilly USA, LLC | $44.52 | 2022 | |
| Abiomed | $41.40 | 2025 | |
| Alexion Pharmaceuticals, INC. | $33.81 | 2024 | Ultomiris |
| Inari Medical, INC. | $27.70 | 2021 | |
| Bard Peripheral Vascular, INC. | $24.12 | 2024 | Fluency Endovascular Stent Graft |
| Kiniksa Pharmaceuticals International, Plc | $23.13 | 2024 | Arcalyst |
| Viiv Healthcare Company | $21.01 | 2022 | |
| Bardy Diagnostics, INC. | $20.82 | 2020 | |
| Altathera Pharmaceuticals LLC | $19.95 | 2025 | Sotalol Hydrochloride |
| Ultragenyx Pharmaceutical INC. | $17.35 | 2023 | |
| Medtronic Vascular, INC. | $17.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.